Recherche - Archive ouverte HAL Accéder directement au contenu

Filtrer vos résultats

85 résultats
Page :
triés par

Evidence for linkage disequilibrium between FcyRIIIa-V158F and FcyRIIa-H131R polymorphisms in Caucasians, and for an FcyRIIIa-restricted influence on the response to therapeutic antibodies.

 Julien Lejeune , Gilles Thibault , David Ternant , Guillaume Cartron , Hervé Watier , et al.
Journal of Clinical Oncology, 2008, 26 (26), pp.1789-96
Article dans une revue hal-00422495v1
Image document

A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations

 Celine Desvignes , David Ternant , Thierry Lecomte , Astrid Lièvre , Marc Ohresser , et al.
Bioanalysis, 2021, 13 (7), pp.565-574. ⟨10.4155/bio-2020-0199⟩
Article dans une revue inserm-03186974v1

Relationship Between Antithymocyte Globulin Concentrations and Lymphocyte Sub-Populations in Kidney Transplant Patients

 Nicolas Azzopardi , Hélène Longuet , David Ternant , Gilles Thibault , Valérie Gouilleux-Gruart , et al.
Clinical Pharmacokinetics, 2022, 61 (1), pp.111-122. ⟨10.1007/s40262-021-01053-7⟩
Article dans une revue hal-04285330v1

Influence of immunogenicity on long-term maintenance of adalimumab in spondyloarthritis

 M Samain , E Ducourau , T Rispens , E. Dernis , F Le Guilchard , et al.
EULAR, Jun 2019, Madrid, Spain
Communication dans un congrès hal-02152564v1

Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis

 Theodora Bejan-Angoulvant , David Ternant , Fadela Daoued , Frédéric Medina , Louis Bernard , et al.
Arthritis & rheumatology, 2017, 69 (1), pp.108-113. ⟨10.1002/art.39841⟩
Article dans une revue hal-01980809v1

Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study

 Guillaume Cartron , Remi Letestu , Caroline Dartigeas , Mira Tout , Beatrice Mahe , et al.
Haematologica, 2018, 103 (8), pp.e356 - e359. ⟨10.3324/haematol.2017.182352⟩
Article dans une revue hal-01860398v1

An Enzyme-Linked Immunosorbent Assay to Study Bevacizumab Pharmacokinetics

 David Ternant , Nicolas Ceze , Thierry Lecomte , Danielle Degenne , Anne-Claire Duveau , et al.
Ther. Drug Monit., 2010, 32 (5), pp.647-652
Article dans une revue hal-00616329v1

An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab

 D. Ternant , N. Ceze , F. Piller , D. Degenne , E. Dorval , et al.
Fundamental & Clinical Pharmacology, 2009, 23, pp.23-23
Article dans une revue hal-00616413v1
Image document

Pharmacokinetics of adalimumab in Crohn’s disease

 David Ternant , Konstantinos Karmiris , Séverine Vermeire , Celine Desvignes , Nicolas Azzopardi , et al.
European Journal of Clinical Pharmacology, 2015, 71 (9), pp.1155-1157. ⟨10.1007/s00228-015-1892-1⟩
Article dans une revue hal-01769822v1

Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule

 Philippe Gatault , Guillaume Brachet , David Ternant , Danielle Degenne , Guillaume Récipon , et al.
mAbs, 2015, 7 (6), pp.1205-1211. ⟨10.1080/19420862.2015.1086049⟩
Article dans une revue hal-02425475v1

Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration

 David Ternant , Christophe Passot , Alexandre Aubourg , Philippe Goupille , Celine Desvignes , et al.
Clinical Pharmacokinetics, 2018, 57 (9), pp.1173-1184. ⟨10.1007/s40262-017-0621-6⟩
Article dans une revue hal-02372850v1
Image document

Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans

 David Ternant , Nicolas Azzopardi , William Raoul , Theodora Bejan-Angoulvant , Gilles Paintaud
Clinical Pharmacokinetics, In press, ⟨10.1007/s40262-018-0680-3⟩
Article dans une revue hal-01821717v1

Development of anti-infliximab antibodies increases infliximab clearance in chronic Inflammatory Bowel Diseases.

 David Ternant , Alexandre Aubourg , Charlotte Magdelaine-Beuzelin , Danielle Degenne , Hervé Watier , et al.
Immunogenicity for Biologics 2008, IBC Congress, Bâle (Suisse), 5-6 février., Feb 2008, BALE, Switzerland
Communication dans un congrès hal-00320459v1

Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease

 David Ternant , Zahir Berkane , Laurence Picon , Valérie Gouilleux-Gruart , Jean-Frédéric Colombel , et al.
Clinical Pharmacokinetics, 2015, 54 (5), pp.551-562. ⟨10.1007/s40262-014-0225-3⟩
Article dans une revue hal-02425490v1

Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients

 Nicolas Azzopardi , Therry Lecomte , David Ternant , Michele Boisdron-Celle , Friedrich Piller , et al.
Fundamental & Clinical Pharmacology, 2011, 25, pp.34-34
Article dans une revue hal-00616314v1

The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition

 Amina Bensalem , Guillaume Cartron , Ulrich Specks , Denis Mulleman , Emmanuel Gyan , et al.
Clinical Pharmacokinetics, 2022, 61 (3), pp.423-437. ⟨10.1007/s40262-021-01081-3⟩
Article dans une revue hal-03482193v1
Image document

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study.

 Mira Tout , Olivier Casasnovas , Michel Meignan , Thierry Lamy , Franck Morschhauser , et al.
Blood, 2017, 129 (19), pp.2616-2623. ⟨10.1182/blood-2016-10-744292⟩
Article dans une revue hal-01547802v1

The underlying inflammatory chronic disease influences infliximab pharmacokinetics

 Christophe Passot , Denis Mulleman , Theodora Bejan-Angoulvant , Alexandre Aubourg , Stephanie Willot , et al.
mAbs, 2016, 8 (7), pp.1407-1416. ⟨10.1080/19420862.2016.1216741⟩
Article dans une revue hal-01980816v1

Confounding mitigation for the exposure‐response relationship of bevacizumab in colorectal cancer patients

 Sarah Lobet , Morgane Caulet , Gilles Paintaud , Nicolas Azzopardi , Céline Desvignes , et al.
British Journal of Clinical Pharmacology, 2024, 90 (4), pp.976-986. ⟨10.1111/bcp.15983⟩
Article dans une revue hal-04525323v1
Image document

Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab / cytotoxic chemotherapy treatment for metastatic colorectal cancer

 Adeline Dolly , Thierry Lecomte , Olivier Bouché , Christophe Borg , Eric Terrebonne , et al.
Clinical Nutrition, 2020, S0261-5614 (20), pp.30080-7. ⟨10.1016/j.clnu.2020.02.017⟩
Article dans une revue inserm-02735513v1

Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial

 Emilie Ducourau , Theo Rispens , Marine Samain , Emmanuelle Dernis , Fabienne Le Guilchard , et al.
RMD Open : Rheumatic & Musculoskeletal Diseases, 2020, 6 (1), pp.e001047. ⟨10.1136/rmdopen-2019-001047⟩
Article dans une revue hal-02439716v1

Infliximab pharmacokinetics in inflammatory Bowel disease patients

 David Ternant , Alexandre Aubourg , Charlotte Magdelaine-Beuzelin , Danielle Degenne , Herve Watier , et al.
Ther. Drug Monit., 2008, 30 (4), pp.523-529
Article dans une revue hal-00616549v1

Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face

 A. Rosen , S. Thimon , David Ternant , M. C. Machet , Gilles Paintaud , et al.
British Journal of Dermatology, 2010, 163 (1), pp.225-227
Article dans une revue hal-00616757v1

FcgRIIIa Expression Is Not Increased on Natural Killer Cells Expressing the FcgRIIIa-158V Allotype.

 Nicolas Congy-Jolivet , Armelle Bolzec , David Ternant , Marc Ohresser , Hervé Watier , et al.
Cancer Research, 2008, 68, pp.976-980
Article dans une revue hal-00317889v1

An enzyme-linked immunosorbent assay for therapeutic drug monitoring of Cetuximab

 David Ternant , Nicolas Cézé , F. Piller , Danielle Degenne , E. Dorval , et al.
Fundam Clin Pharmacol, Apr 2009, MARSEILLE, France
Communication dans un congrès hal-00375861v1

Mise au point d'une méthode de dosage sérique du cétuximab appliquée au suivi thérapeutique des patients traités.

 Nicolas Cézé , David Ternant , F. Piller , Danielle Degenne , Hervé Watier , et al.
Journées Francophones de Pathologie Digestive, Paris, mars 2008., Mar 2008, PARIS, France. pp.51
Communication dans un congrès hal-00320376v1

Nonlinear pharmacokinetics of rituximab in anti-neutrophil cytoplasmic antibody associated vasculitis.

 Denis Mulleman , Amina Bensalem , David Ternant , Gilles Paintaud , Divi Cornec , et al.
EULAR 2019, Jun 2019, MADRID, Spain
Poster de conférence hal-02151041v1
Image document

Curcumin and NCLX inhibitors share anti-tumoral mechanisms in microsatellite-instability-driven colorectal cancer

 Maxime Guéguinou , Sajida Ibrahim , Jérôme Bourgeais , Alison Robert , Trayambak Pathak , et al.
Cellular and Molecular Life Sciences, 2022, 79 (6), pp.article n° 284. ⟨10.1007/s00018-022-04311-4⟩
Article dans une revue hal-03668944v1

Tumor burden influences exposure and response to rituximab : pharmacokinetic - pharmacodynamic modelling using a syngeneic bioluminescent murine model expressing human CD20

 David Dayde , David Ternant , Marc Ohresser , S. Lerondel , S. Pesnel , et al.
Blood, 2009, 113, pp.3765-3772
Article dans une revue hal-00422647v1
Image document

P2X7 Receptor Promotes Mouse Mammary Cancer Cell Invasiveness and Tumour Progression, and Is a Target for Anticancer Treatment

 Lucie Brisson , Stéphanie Chadet , Osbaldo Lopez-Charcas , Bilel Jelassi , David Ternant , et al.
Cancers, 2020, 12 (9), pp.2342. ⟨10.3390/cancers12092342⟩
Article dans une revue hal-03100046v1
Page :